Compare TSBK & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TSBK | ALLO |
|---|---|---|
| Founded | 1915 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 306.8M | 252.9M |
| IPO Year | 1997 | 2018 |
| Metric | TSBK | ALLO |
|---|---|---|
| Price | $38.03 | $2.09 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $8.27 |
| AVG Volume (30 Days) | 15.6K | ★ 6.4M |
| Earning Date | 04-28-2026 | 01-01-0001 |
| Dividend Yield | ★ 2.97% | N/A |
| EPS Growth | 21.93 | ★ 36.84 |
| EPS | ★ 1.04 | N/A |
| Revenue | N/A | ★ $22,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $37.53 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $27.51 | $0.86 |
| 52 Week High | $40.41 | $2.32 |
| Indicator | TSBK | ALLO |
|---|---|---|
| Relative Strength Index (RSI) | 48.57 | 62.18 |
| Support Level | $30.95 | $1.01 |
| Resistance Level | $38.18 | N/A |
| Average True Range (ATR) | 0.78 | 0.17 |
| MACD | -0.18 | 0.04 |
| Stochastic Oscillator | 7.93 | 70.95 |
Timberland Bancorp Inc is a bank holding company for Timberland Bank. The bank offers banking services including personal checking and savings accounts, debit cards, health savings accounts, online and mobile banking, online bill pay, 24-hour phone banking, and Zelle. Business services include business checking accounts, online banking, remote deposit, ACH transactions, Autobooks, and insured cash sweep services. The bank also provides lending services such as personal credit cards, home loans, home equity borrowing, construction loans, and SBA loans. In addition, it offers loans to real estate, including residential and commercial real estate, multi-family construction loans, one- to four-family residential loans, multi-family loans, commercial real estate loans, and land loans.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.